Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CSL
Biotech
CSL pays $117M for option on phase 3 blood clotting specialist
CSL has moved quickly to spend some of the money freed up by recent cuts, securing an option to buy VarmX in return for $117 million upfront.
Nick Paul Taylor
Sep 16, 2025 4:31am
CSL to lose up to 15% of staff, cut R&D costs, spin out vaccines
Aug 19, 2025 7:06am
CSL consolidates R&D team in shift toward external partners
Jul 7, 2025 12:44pm
CSL's largest ph. 3 trial ends in failure for heart attack drug
Feb 12, 2024 5:21am
Genexine's anemia drug matches Roche-CSL product in phase 3
Apr 11, 2023 8:05am
CSL links drug to rare disease benefits, plans global filings
Feb 27, 2023 10:15am
